Market Place
Sourcing Support
AltruBio Announces Formation of Scientific Advisory Board
03 Dec 2024 //
GLOBENEWSWIRE
AltruBio to Attend Jefferies & Piper Sandler Conferences
12 Nov 2024 //
GLOBENEWSWIRE
AltruBio Presents ALTB-268 In Vivo Data at FIMSA 2024 Congress
28 Oct 2024 //
#N/A
AltruBio secures $225m for immune checkpoint programme development
22 May 2024 //
PHARMACEUTICAL TECHNOLOGY
AltruBio Raises $225M Series B For Immune Checkpoint Program
21 May 2024 //
GLOBENEWSWIRE
AltruBio to Participate in Upcoming May 2024 Medical Conferences
01 May 2024 //
GLOBENEWSWIRE
AltruBio Announces Enrollment of First Patient in Phase 2 Program of ALTB-268
07 Dec 2023 //
GLOBENEWSWIRE
AltruBio Announces FDA Clearance of IND Application for ALTB-268
26 Sep 2023 //
GLOBENEWSWIRE
AltruBio Announces Positive Topline Data from Phase 1 Trial of ALTB-268
01 Aug 2023 //
GLOBENEWSWIRE
AltruBio to Present at the Federation of (FOCIS) 2023 Annual Meeting
15 Jun 2023 //
GLOBENEWSWIRE
AltruBio to Present at the 2023 BIO International Convention
31 May 2023 //
GLOBENEWSWIRE
AltruBio Announces Poster Presentation at Digestive Disease Week Conference 2023
08 May 2023 //
GLOBENEWSWIRE
AltruBio Announces Panels & Presentations at Three March Healthcare Conferences
09 Mar 2023 //
GLOBENEWSWIRE
AltruBio Announces Poster Presentation on Immune Checkpoint Enhancer, ALTB-168
19 Jan 2023 //
GLOBENEWSWIRE
AltruBio to Present at Biotech Showcaseâ„¢ 2023
05 Jan 2023 //
GLOBENEWSWIRE
AltruBio Presents Data from Phase 1b Study Evaluating ALTB-168 in Patients
10 Dec 2022 //
GLOBENEWSWIRE
AltruBio Hosting R&D Update on Immune Checkpoint Enhancer Platform
08 Dec 2022 //
GLOBENEWSWIRE
AltruBio Announces FDA Clearance of IND Application for ALTB-268
06 Dec 2022 //
GLOBENEWSWIRE
AltruBio to Present New Phase 1b Data Evaluating Neihulizumab (ALTB-168)
03 Nov 2022 //
GLOBENEWSWIRE
AltruBio President and CEO Judy Chou Appointed to the Gov Board of California
01 Nov 2022 //
GLOBENEWSWIRE
AltruBio President and CEO Judy Chou to Participate at the Longwood
16 Sep 2022 //
GLOBENEWSWIRE
AltruBio to Present at the 2022 BIO International Convention
06 Jun 2022 //
GLOBENEWSWIRE
AltruBio Completes Enrollment in PI Study of Neihulizumab in SR-aGVHD
12 May 2022 //
GLOBENEWSWIRE
AltruBio to Present at BIO CEO & Investor Conference
07 Feb 2022 //
GLOBENEWSWIRE
AltruBio to Present Abstract on Checkpoint Regulator Neihulizumab Novel Therapy
06 Oct 2021 //
GLOBENEWSWIRE
AltruBio snags new CMO with pivot to immunology—Chutes & Ladders
17 Sep 2021 //
FIERCEBIOTECH
AltruBio Appoints Jesse Hall
13 Sep 2021 //
GLOBENEWSWIRE
After a major facelift, AltruBio says it`s ready for a pivotal fight against
15 Apr 2021 //
ENDPTS
All-new AltruBio relaunches with $63M Series A
15 Apr 2021 //
FIERCEBIOTECH
AltruBio’s Neihulizumab Granted Fast Track Designation by the FDA
08 Mar 2021 //
GLOBENEWSWIRE
AltruBio Announces First Patient Dosed in Phase 1b Study of Neihulizumab
29 Sep 2020 //
PRESS RELEASE
AltruBio moves forward with clinical development of Neihulizumab in Steroid
01 Jul 2020 //
PIPELINEREVIEW
